Journal Home
Search for

Volume 53, Issue 1, Pages 33-40 (January 2009)


View previous. 7 of 34 View next.

Meta-analysis of N-Acetylcysteine to Prevent Acute Renal Failure After Major Surgery

Kwok M. Ho, MBBS, MPH, FRCP, FANZCA, FJFICMCorresponding Author Informationemail address, David J.R. Morgan, MBBS, FACEM, FJFICM

Received 12 February 2008; accepted 7 May 2008. published online 24 July 2008.

Background

Acute renal failure after major surgery is associated with significant mortality and morbidity that theoretically may be attenuated by N-acetylcysteine.

Design

Meta-analysis of relevant studies sourced from the Cochrane Controlled Trial Register (2007 issue 4), EMBASE, and MEDLINE databases (1966 to February 1, 2008) without language restriction.

Setting & Population

Adult patients undergoing major surgery without the use of radiocontrast.

Selection Criteria for Studies

Randomized controlled studies comparing N-acetylcysteine with a placebo perioperatively.

Data Analysis

Categorical variables are reported as odds ratio (OR) with 95% confidence interval (CI), and continuous variables are reported as weighted-mean-difference (WMD) with 95% CI.

Outcome Measures

Effects of N-acetylcysteine on mortality and acute renal failure requiring dialysis were the main outcomes of interest. Additional outcome measures included an incremental increase in serum creatinine concentration greater than 25% above baseline, surgical reexploration for bleeding, amount of allogeneic blood transfusion, and length of intensive care unit stay.

Results

10 studies involving a total of 1,193 adult patients undergoing major surgery were considered. N-Acetylcysteine use was not associated with a decrease in mortality (OR, 1.05; 95% CI, 0.58 to 1.92), acute renal failure requiring dialysis (OR, 1.04; 95% CI, 0.45 to 2.37), incremental increase in serum creatinine concentration greater than 25% above baseline (OR, 0.84; 95% CI, 0.64 to 1.11), or length of intensive care unit stay (WMD in days, 0.46; 95% CI, −0.43 to 1.36). N-Acetylcysteine did not appear to increase the risk of surgical reexploration for bleeding (OR, 1.16; 95% CI, 0.57 to 2.38) or amount of allogeneic blood transfusion required (WMD in units, 0.31; 95% CI, −0.21 to 0.84).

Limitations

Most studied patients had cardiac surgery and normal renal function preoperatively.

Conclusions

There is no current evidence that N-acetylcysteine used perioperatively can alter mortality or renal outcomes when radiocontrast is not used.

Intensive Care Unit, Royal Perth Hospital, Perth, WA, Australia

Corresponding Author InformationAddress correspondence to Kwok M. Ho, MBBS, MPH, FRCP, FANZCA, FJFICM, ICU, Royal Perth Hospital, Perth, WA 6000, Australia

 Originally published online as doi:10.1053/j.ajkd.2008.05.019 on July 25, 2008.

PII: S0272-6386(08)00958-X

doi:10.1053/j.ajkd.2008.05.019


View previous. 7 of 34 View next.